The much-anticipated findings from two phase III clinical trials of new therapies for patients with metastatic melanoma did not disappoint those in attendance at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week.
The trials confirmed that the molecularly targeted agent vemurafenib and the immunotherapy agent ipilimumab (Yervoy) offer valuable new options for a disease in which effective treatments have been lacking. Read more > >
New Substances Added to HHS Report on Carcinogens
Last Friday, the Department of Health and Human Services added eight substances to its Report on Carcinogens, a science-based document that identifies chemicals and biological agents that may put people at increased risk for cancer. Formaldehyde and aristolochic acids are listed as known human carcinogens, and six other substances were added as reasonably anticipated to be human carcinogens.
For more information, read the NIEHS press release.
- FDA Announces Changes to Sunscreen Labels
- No Link Found between Hypertension Drugs and Cancer
- Thermography Is No Substitute for Mammography, FDA Warns
- NCI Director Announces New Staff Appointments
- Abstracts Sought for Annual Molecular Markers in Cancer Meeting
- Research to Reality Cyber-Seminar Will Feature Community Impact Program
- NCI Cancer Classroom Webinar Series Continues June 28
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.